SL-052

• Description :

  SL-052 is a hypocrellin-based photosensitizer that has recently shown promising results in clinical and preclinical testing for cancer photodynamic therapy (PDT) . SL-052 is encapsulated in biodegradable polylactic-co-glycolic acid (PLGA) polymer nanoparticles optimized using single emulsion solvent evaporation technology. The SL-052-PLGA nanoparticles were more effective in PDT treatment of subcutaneous SCCVII squamous cell carcinoma compared to polyvinylpyrrolidone (PVP) -based and standard liposomal SL-052 formulations. A longer time interval between drug injection and tumor illumination can improve tumor cure rates, and SL-052-PLGA nanoparticles showed the best therapeutic effect among all SL-052 formulations.

• UNSPSC :

  12352005

• Target :

  Photosensitizer

• Type :

  Reference compound

• Related Pathways :

  Apoptosis

• Applications :

  Cancer-programmed cell death

• Field of Research :

  Cancer

• Assay Protocol :

  https://www.medchemexpress.com/sl-052.html

• Smiles :

  COC(C([C@H](C(C)=CC1=C(N[C@](CCCC2)([H])[C@@]2([H])N3)C3=C4C5=O)C(C)=O)=C6C1=C4C(C(OC)=C5)=C7C6=C8C(C=C7OC)=O)=C8O

• Molecular Formula :

  C35H32N2O7

• Molecular Weight :

  592.64

• References & Citations :

  [1]Antitumor Efficacy of Photodynamic Therapy Using Novel Nanoformulations of Hypocrellin Photosensitizer SL052

• Shipping Conditions :

  Room temperature

• Scientific Category :

  Reference compound1

• Clinical Information :

  No Development Reported

• CAS Number :

  [925438-34-2]